Namilumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Namilumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CSF2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒N☑Y (what is this?)  (verify)

Namilumab (alternative identifier MT203) is a human monoclonal antibody (class IgG1 kappa) that targets granulocyte macrophage-colon stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis.[1][2][3] Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis[4] and rheumatoid arthritis.[5][6]

Namilumab was produced by Micromet Inc and is under development by Takeda Pharmaceuticals International.[3][7]

References[edit]